Hunan Jingfeng Pharmaceutical

SHE:000908 China Drug Manufacturers - General
Market Cap
$605.52 Million
CN¥4.44 Billion CNY
Market Cap Rank
#14971 Global
#3992 in China
Share Price
CN¥5.05
Change (1 day)
+4.99%
52-Week Range
CN¥3.85 - CN¥9.23
All Time High
CN¥16.99
Categories
Companies in China Drug Manufacturers - General
About

Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more

Hunan Jingfeng Pharmaceutical (000908) - Net Assets

Latest net assets as of September 2025: CN¥-37.76 Million CNY

Based on the latest financial reports, Hunan Jingfeng Pharmaceutical (000908) has net assets worth CN¥-37.76 Million CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥877.99 Million) and total liabilities (CN¥915.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥-37.76 Million
% of Total Assets -4.3%
Annual Growth Rate N/A
5-Year Change -102.37%
10-Year Change -100.67%
Growth Volatility 3858.7

Hunan Jingfeng Pharmaceutical - Net Assets Trend (1995–2024)

This chart illustrates how Hunan Jingfeng Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Hunan Jingfeng Pharmaceutical (1995–2024)

The table below shows the annual net assets of Hunan Jingfeng Pharmaceutical from 1995 to 2024.

Year Net Assets Change
2024-12-31 CN¥-15.13 Million +90.16%
2023-12-31 CN¥-153.68 Million -171.54%
2022-12-31 CN¥214.83 Million -34.45%
2021-12-31 CN¥327.73 Million -48.65%
2020-12-31 CN¥638.18 Million -67.13%
2019-12-31 CN¥1.94 Billion -32.15%
2018-12-31 CN¥2.86 Billion +10.08%
2017-12-31 CN¥2.60 Billion -0.48%
2016-12-31 CN¥2.61 Billion +16.19%
2015-12-31 CN¥2.25 Billion +126.19%
2014-12-31 CN¥994.04 Million +18624.95%
2013-12-31 CN¥5.31 Million +108.82%
2012-12-31 CN¥-60.15 Million -7706.65%
2011-12-31 CN¥790.82K -98.63%
2010-12-31 CN¥57.85 Million -42.54%
2009-12-31 CN¥100.67 Million -70.27%
2008-12-31 CN¥338.64 Million +0.50%
2007-12-31 CN¥336.95 Million +0.17%
2006-12-31 CN¥336.40 Million +2.04%
2005-12-31 CN¥329.66 Million -2.88%
2004-12-31 CN¥339.45 Million -19.06%
2003-12-31 CN¥419.38 Million -19.77%
2002-12-31 CN¥522.69 Million +4.87%
2001-12-31 CN¥498.41 Million -0.43%
2000-12-31 CN¥500.54 Million +3.11%
1999-12-31 CN¥485.43 Million +21.17%
1998-12-31 CN¥400.62 Million +363.09%
1997-12-31 CN¥86.51 Million +42.21%
1996-12-31 CN¥60.83 Million +97.55%
1995-12-31 CN¥30.79 Million --

Equity Component Analysis

This analysis shows how different components contribute to Hunan Jingfeng Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 104595230500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CN¥416.69 Million 509.42%
Other Comprehensive Income CN¥-305.87 Million -373.95%
Other Components CN¥1.02 Billion 1243.25%
Total Equity CN¥81.80 Million 100.00%

Hunan Jingfeng Pharmaceutical Competitors by Market Cap

The table below lists competitors of Hunan Jingfeng Pharmaceutical ranked by their market capitalization.

Company Market Cap
Elematec Corporation
PINK:EEAEF
 		$202.87 Million
ANY Security Printing PLC
BUD:ANY
 		$202.87 Million
Accent Group Ltd
AU:AX1
 		$202.88 Million
Zhejiang Jinsheng New Materials Co
SHE:300849
 		$202.88 Million
Sesoda Corp
TW:1708
 		$202.84 Million
Devsisters corporation
KQ:194480
 		$202.76 Million
Vastned Retail NV
AS:VASTN
 		$202.76 Million
Pecoy Copper Corp.
V:PCU
 		$202.74 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hunan Jingfeng Pharmaceutical's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from -49,494,383 to 81,796,189, a change of 131,290,572.
  • Net income of 152,304,308 contributed positively to equity growth.
  • Dividend payments of 13,403,077 reduced retained earnings.
  • Other comprehensive income decreased equity by 57,367.
  • Other factors decreased equity by 7,553,292.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥152.30 Million +186.2%
Dividends Paid CN¥13.40 Million -16.39%
Other Comprehensive Income CN¥-57.37K -0.07%
Other Changes CN¥-7.55 Million -9.23%
Total Change CN¥- %

Book Value vs Market Value Analysis

This analysis compares Hunan Jingfeng Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 54.32x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 64.26x to 54.32x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.08 CN¥5.05 x
1996-12-31 CN¥0.16 CN¥5.05 x
1997-12-31 CN¥0.22 CN¥5.05 x
1998-12-31 CN¥1.02 CN¥5.05 x
1999-12-31 CN¥1.16 CN¥5.05 x
2000-12-31 CN¥1.25 CN¥5.05 x
2001-12-31 CN¥1.27 CN¥5.05 x
2002-12-31 CN¥1.30 CN¥5.05 x
2003-12-31 CN¥1.02 CN¥5.05 x
2004-12-31 CN¥0.83 CN¥5.05 x
2005-12-31 CN¥0.84 CN¥5.05 x
2006-12-31 CN¥0.85 CN¥5.05 x
2007-12-31 CN¥1.07 CN¥5.05 x
2008-12-31 CN¥0.87 CN¥5.05 x
2009-12-31 CN¥0.17 CN¥5.05 x
2010-12-31 CN¥0.19 CN¥5.05 x
2011-12-31 CN¥0.00 CN¥5.05 x
2012-12-31 CN¥-0.20 CN¥5.05 x
2013-12-31 CN¥0.01 CN¥5.05 x
2014-12-31 CN¥1.95 CN¥5.05 x
2015-12-31 CN¥2.48 CN¥5.05 x
2016-12-31 CN¥2.72 CN¥5.05 x
2017-12-31 CN¥2.70 CN¥5.05 x
2018-12-31 CN¥2.82 CN¥5.05 x
2019-12-31 CN¥1.81 CN¥5.05 x
2020-12-31 CN¥0.59 CN¥5.05 x
2021-12-31 CN¥0.35 CN¥5.05 x
2022-12-31 CN¥0.20 CN¥5.05 x
2023-12-31 CN¥-0.06 CN¥5.05 x
2024-12-31 CN¥0.09 CN¥5.05 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hunan Jingfeng Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 186.20%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 36.61%
  • • Asset Turnover: 0.44x
  • • Equity Multiplier: 11.49x
  • Recent ROE (186.20%) is above the historical average (-602.53%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 25.85% 11.80% 1.02x 2.15x CN¥4.88 Million
1996 30.68% 27.21% 0.52x 2.16x CN¥12.58 Million
1997 31.04% 40.76% 0.50x 1.53x CN¥18.20 Million
1998 7.32% 33.97% 0.18x 1.18x CN¥-10.72 Million
1999 12.50% 41.77% 0.20x 1.52x CN¥11.37 Million
2000 9.42% 24.44% 0.27x 1.42x CN¥-2.83 Million
2001 2.46% 7.15% 0.28x 1.25x CN¥-37.50 Million
2002 2.74% 6.54% 0.25x 1.70x CN¥-37.10 Million
2003 -13.17% -24.30% 0.22x 2.45x CN¥-92.83 Million
2004 -20.03% -25.17% 0.29x 2.74x CN¥-97.58 Million
2005 0.91% 1.39% 0.26x 2.56x CN¥-29.84 Million
2006 0.81% 1.15% 0.29x 2.46x CN¥-30.75 Million
2007 1.69% 3.01% 0.23x 2.44x CN¥-27.73 Million
2008 -11.48% -15.45% 0.22x 3.39x CN¥-62.65 Million
2009 -444.36% -100.88% 0.30x 14.63x CN¥-243.81 Million
2010 5.22% 1.38% 0.46x 8.23x CN¥-2.74 Million
2011 -17638.33% -40.98% 0.33x 1304.81x CN¥-57.00 Million
2012 0.00% -41.85% 0.39x 0.00x CN¥-54.75 Million
2013 68.17% 2.01% 0.50x 68.14x CN¥2.87 Million
2014 25.58% 12.82% 1.02x 1.95x CN¥152.91 Million
2015 14.91% 13.18% 0.71x 1.58x CN¥106.74 Million
2016 14.21% 12.88% 0.51x 2.15x CN¥100.81 Million
2017 6.81% 6.27% 0.53x 2.05x CN¥-75.76 Million
2018 7.52% 7.22% 0.49x 2.10x CN¥-61.55 Million
2019 -58.03% -68.57% 0.31x 2.74x CN¥-1.08 Billion
2020 -222.16% -131.60% 0.33x 5.17x CN¥-1.21 Billion
2021 -65.81% -24.86% 0.45x 5.85x CN¥-232.28 Million
2022 -56.70% -12.00% 0.57x 8.25x CN¥-118.68 Million
2023 0.00% -32.75% 0.62x 0.00x CN¥-210.19 Million
2024 186.20% 36.61% 0.44x 11.49x CN¥144.12 Million

Industry Comparison

This section compares Hunan Jingfeng Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

  • Industry: Drug Manufacturers - General
  • Average net assets among peers: $1,532,528,653
  • Average return on equity (ROE) among peers: 11.35%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hunan Jingfeng Pharmaceutical (000908) CN¥-37.76 Million 25.85% N/A $202.85 Million
Zhejiang Int'L Group Co Ltd (000411) $177.19 Million 13.55% 0.63x $201.14 Million
Zhejiang Zhenyuan Share Co Ltd (000705) $280.61 Million 7.70% 0.99x $310.45 Million
Hubei Guangji Pharmaceutical Co Ltd (000952) $477.68 Million 3.28% 0.64x $234.89 Million
Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) $361.29 Million 26.02% 0.32x $146.91 Million
Yifan Xinfu Pharmaceutical Co Ltd (002019) $9.15 Billion 2.09% 0.37x $1.03 Billion
Guangdong Jiaying Pharmaceutical Co Ltd (002198) $278.08 Million 2.72% 0.13x $459.10 Million
Chongqing Lummy Pharmaceutical (300006) $107.91 Million 22.70% 0.99x $476.38 Million
Zhejiang Jolly Pharmaceutical Co Ltd (300181) $1.44 Billion 5.91% 0.29x $1.19 Billion
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) $1.53 Billion 18.22% 0.05x $893.48 Million